Alnylam and Regeneron unveil RNAi partnership

09-04-2019

Alnylam and Regeneron unveil RNAi partnership

peopleimages / iStockphoto.com

Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference (RNAi) therapeutics.


Alnylam, Regeneron, RNA, RNAi, eye, central nervous system, CNS, commercialisation, disease

LSIPR